This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis
This guideline covers one-to-one interventions to prevent sexually transmitted infections (STIs) and under-18 conceptions. The aim is to reduce the transmission of chlamydia and other STIs, including HIV, and reduce the rate of pregnancies among women aged under 18.
Evidence-based recommendations on routine antenatal anti-D prophylaxis for women who are rhesus D negative
Evidence-based recommendations on varenicline (Champix) to help people stop smoking
Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
Evidence-based recommendations on cetuximab (Erbitux) for the treatment of locally advanced squamous cell cancer of the head and neck
Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer
Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults
Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis
Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome
Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours (cancer of stomach/digestive system)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on febuxostat (Adenuric) for the management of hyperuricaemia in people with gout
Evidence-based recommendations on bivalirudin (Angiox) for treating ST-segment-elevation myocardial infarction (STEMI)
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma (bone marrow cancer)
Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults
Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)
Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer
Evidence-based recommendations on pemetrexed disodium (Alimta) for the first-line treatment of non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults not previously treated with ipilimumab
Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C
Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B
Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women
Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)
Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating Crohn's disease in adults
Evidence-based recommendations on mifamurtide (Mepact) for treatment of osteosarcoma (bone cancer)
Evidence-based recommendations on rituximab (MabThera) for first-line maintenance treatment of follicular non-Hodgkin's lymphoma
Evidence-based recommendations on vemurafenib (Zelboraf) for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes